Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
VHL patients may benefit from sunitinib. This study will investigate the following objectives
:
PRIMARY OBJECTIVE
- To determine the objective response rate according to RECIST criteria, in VHL patients
with advanced tumors or tumors untreatable by other means, and treated with sunitinib.
SECONDARY OBJECTIVES
- To evaluate the safety and tolerability of sunitinib in VHL patients according to the
NCI-CTC criteria Version 3.0.
- To determine the following time-to-event endpoints: overall survival, time to disease
progression, progression free survival, time to response and duration of response.
- To evaluate quality of life in VHL patients receiving sunitinib.